Comparison of Bevacizumab and Aflibercept for Suppression of Angiogenesis in Human Retinal Microvascular Endothelial Cells

Bevacizumab (Avastin) is a vascular endothelial growth factor (VEGF) inhibitor that is widely used for aggressive posterior retinopathy of prematurity (APROP). Its use is associated with multiple adverse effects. Aflibercept (Eylea) is a VEGFR-1 analogue that is approved for ocular use, but its effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yazdanyar, Amirfarbod, Cai, Charles L., Aranda, Jacob V., Shrier, Eric, Beharry, Kay D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383229/
https://www.ncbi.nlm.nih.gov/pubmed/37513851
http://dx.doi.org/10.3390/ph16070939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383229/
https://www.ncbi.nlm.nih.gov/pubmed/37513851
http://dx.doi.org/10.3390/ph16070939

Ejemplares similares